Curaleaf sees Q4 revenue $330M vs. $327.8M last year

TipRanks

Wed, January 21, 2026 astatine 7:44 AM CST 1 min read

Q4 nett gross excluding the discontinued businesses is expected to beryllium astatine slightest $330M, implying astir 4% sequential maturation compared to Q3 2025 nett gross of $317.8M, supra the erstwhile guidance scope of debased azygous digit growth. Q4 nett gross is expected to turn astir 1% compared to Q4 2024 nett gross of $327.8M. Q4 adjusted gross nett borderline excluding the discontinued businesses is expected to beryllium astir 48.5%. Comparable adjusted gross nett borderline for Q4 2024 was 48.5%. Full twelvemonth 2025 adjusted gross borderline is expected to beryllium astir 50%. “Our preliminary Q4 results show that the ‘Return to Our Roots’ strategy has delivered wide impact, with coagulated gross maturation and sustained beardown margins. We person besides made the strategical determination to upwind down our hemp concern owed to caller national regulations prohibiting hemp-derived THC products containing THC supra 0.3%, and exit Missouri arsenic a sub-scale beingness successful the authorities did not warrant continued investment,” said Boris Jordan, Chairman and CEO of Curaleaf (CURLF). “Having completed this reset inaugural astatine the extremity of Q4, we’re closing the twelvemonth connected a precocious enactment with a coagulated instauration successful spot to thrust renewed momentum and show successful 2026. As we physique connected this progress, we stay focused connected maintaining a robust equilibrium expanse portion completing the refinancing of our elder secured notes owed December 2026, guided by our broad superior allocation and liquidity strategy.”